研究发现,在怀孕之前或怀孕期间阻止Ozempic等GLP-1药物会增加体重增加和并发症的风险。 Stopping GLP-1 drugs like Ozempic before or during pregnancy raises risks of weight gain and complications, study finds.

阻止GLP-1体重减少药物(如Ozempic)的妇女,在怀孕之前或怀孕期间,面临过重增加、妊娠糖尿病、高血压和早产等较高风险,牙买加医学协会对近1 800例怀孕进行了一项研究。 Women who stop GLP-1 weight loss drugs like Ozempic before or during pregnancy face higher risks of excessive weight gain, gestational diabetes, hypertension, and preterm birth, a JAMA study of nearly 1,800 pregnancies found. 停止使用这些药物的人平均增加7.2磅,并大大增加了并发症的风险,尽管在剖腹产率或婴儿大小方面没有出现差异。 Those who discontinued the drugs gained an average of 7.2 more pounds and had significantly increased risks of complications, though no differences were seen in cesarean rates or baby size. 专家们强调,在停止使用这些药物时,需要在体重和健康管理方面提供更好的指导,特别是考虑到这些药物在怀孕前对肥胖和新陈代谢健康具有已知的好处。 Experts stress the need for better guidance on managing weight and health when stopping these medications, especially given their known benefits for obesity and metabolic health prior to pregnancy.